The National Comprehensive Cancer Network Guidelines recommends testing a panel of genes for NSCLC, which consists of epidermal growth factor (EGFR) mutations, anapestic lymphoma kinase (ALK) rearrangements, and c-ros oncogene 1 (ROS1) rearrangements. This evidence concerns the gene EGFR and non-small cell lung carcinoma.